Micro-RNA: New players in HIV-pathogenesis, diagnosis, prognosis and antiviral therapy

AIDS Reviews

Volumn 15, Issue 1, 2013, Pages 3-14

  Fowler, Lauren ^a   Saksena, Nitin K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biological markers; Gene expression profiling; HIV 1; MicroRNA; Virus latency

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MESSENGER RNA; MICRORNA; MICRORNA 1224 3P; MICRORNA 125B; MICRORNA 150; MICRORNA 15A; MICRORNA 15B; MICRORNA 16; MICRORNA 17 5P; MICRORNA 198; MICRORNA 20A; MICRORNA 223; MICRORNA 24; MICRORNA 28; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 382; MICRORNA H1; NEF PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; CANCER INHIBITION; CARCINOGENESIS; CD4+ T LYMPHOCYTE; DISEASE COURSE; DNA DAMAGE; EXPERIMENTAL HOST; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; GENE SILENCING; GENE TARGETING; GENETIC PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; LEUKOCYTE; LONG TERMINAL REPEAT; NEOPLASM; NONHUMAN; ONCOGENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVIEW; RNA STRUCTURE; RNA VIRUS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS LATENCY; VIRUS PATHOGENESIS;

ANTI-HIV AGENTS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICRORNAS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84881404325     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. UNAIDS. World Aids Day Report; 2011.
2. Houzet L, Jeang K. MicroRNAs and human retroviruses. Biochim Biophys Acta. 2011;1809:686-93.
3. Calin G, Sevignani C, Dumitru C, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999-3004.
4. Croce C. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-14.
5. Calin G, Dumitru C, Shimizu M, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524-9.
6. Bartel D. MicroRNAs-Genomics, Review Biogenesis, Mechanism, and Function. Cell. 2004;116:281-97.
7. Ambros V, Bartel B, Bartel D, et al. A uniform system for microRNA annotation. RNA. 2003;9:277-9.
8. Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari SK. Host-virus interaction: a new role for microRNAs. Retrovirology. 2006;3:68.
9. Mineno J, Okamoto S, Ando T, et al. The expression profile of microRNAs in mouse embryos. Nucleic Acids Res. 2006;34:1765-71.
10. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett. 2005;579:5904-10.
11. Han J, Lee Y, Yeom K, Kim Y, Jin H, Kim V. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18:3016-27.
12. Yi R, Qin Y, Macara I, Cullen B. Exportin-5 mediates the nuclear export of premicroRNAs and short hairpin RNAs. Genes Dev. 2003;17:3011-16.
13. Schwartz D, Hutvagner G, Du T, Xu Z, Aronin N, Zamore P. Asymmetry in the Assembly of the RNAi Enzyme Complex. Cell. 2003;115:199-208.
14. Wang Y, Juranek S, Li H, Sheng G, Wardle G, Tuschl T. Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature. 2009;461:754-61.
15. Narayanan A, Kehn-Hall K, Bailey C, Kashanchi F. Analysis of the roles of HIVderived microRNAs. Exp Op Biol Theor. 2011;11:17-29.
16. Pillai R, Bhattacharyya S, Artus C, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309:1573-6.
17. Catalucci D, Latronico M, Condorelli G. MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann NY Acad Sci. 2008;1123:20-9.
18. Bartel D. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-33.
19. Kulkarni M. On track with P-bodies. Biochem Soc Trans. 2010;38:242.
20. Buhler M, Moazed D. Transcription and RNAi in heterochromatic gene silencing. Nat Struct Mol Biol. 2007;14:1041-8.
21. Lewis B, Burge C, Bartel D. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
22. Friedman R, Farh K, Burge C, Bartel D. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92-105.
23. John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D. Human MicroRNA targets. PLoS Biol. 2004;2:e363.
24. Chen J, Mandel E, Thomson J, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38:228-33.
25. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18:79-88.
26. Lu J, Getz G, Miska E, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8.
27. Boss I, Renne R. Viral miRNAs: tools for immune evasion. Curr Opin Microbiol. 2010;13:540-5.
28. Lecellier C, Dunoyer P, Arar K, et al. A cellular microRNA mediates antiviral defense in human cells. Science. 2005;308:557-560.
29. Jopling C, Yi M, Lancaster A, Lemon S, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81.
30. Godshalk S, Bhaduri-McIntosh S, Slack F. Epstein-Barr virus-mediated dysregulation of human microRNA expression. Cell Cycle. 2008; 7:3595-600.
31. Kutok J, Wang F. Spectrum of Epstein-Barr virus-associated diseases Ann Rev Pathol. 2006;1:375-404.
32. Watanabe Y, Kishi A, Yachie N, Kanai A, Tomita M. Computational analysis of microRNA-mediated antiviral defense in humans. FEBS Lett. 2007;581:4603-10.
33. Hayes A, Qian S, Yu L, Boris-Lawrie K. Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology. 2011;8:36.
34. Triboulet R, Mari B, Lin Y, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007;315:1579-82.
35. Yeung M, Bennasser Y, Myers T, Jiang G, Benkirane M, Jeang K. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology. 2005;2:81.
36. Houzet L, Yeung M, de Lame V, Desai D, Smith S, Jeang K. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology. 2008;5:118.
37. Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007; 13:1241-7.
38. Witwer K, Watson A, Blankson J, Clements J. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology. 2012;9:5.
39. Zhu L, Qui C, Qui C, et al. Poster MOPE026 -MicroRNA profile identifies different outcomes of disease progression at later stage of HIV infection. XIX IAS Conference, Washington DC; 2012.
40. Kedzierska K, Crowe S. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem. 2002;9:1893-903.
41. Wang X, Ye L, Zhou Y, Wang Y, Metzger D, Ho W. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood. 2009;113:671-4.
42. Wang X, Ye L, Zhou Y, Liu M, Zhou D, Ho W. Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Path. 2011;178:41-7.
43. Swaminathan S, Zaunders J, Wilkinson J, Suzuki K, Kelleher A. Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection? Blood. 2009;113:5029-30.
44. Hariharan M, Scaria V, Pillai B, Brahmachari S. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun. 2005;337:1214-18.
45. Ahluwalia J, Khan S, Soni K, et al. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV1 replication. Retrovirology. 2008;5:117.
46. Sun G, Li H, Wu X, et al. Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res. 2012;40:2181-96.
47. Nathans R, Chu C, Serquina A, Lu C, Cao H, Rana T. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell. 2009; 34:696-709.
48. Tan-gana N, Victoriano A, Hibi Y, Asamitsu K, Uranishi H, Okamoto T. Poster TUPE005 -Interactions of cellular microRNAs in HIV-1 latently infected cells. XIX IAS Conference, Washington DC; 2012.
49. Pfeffer S, Zavolan M, Grasser F, et al. Identification of virus encoded miRNAs. Science. 2004;304:734-6.
50. Pfeffer S, Sewer A, Lagos-Quintana M, et al. Identification of microRNAs of the herpesvirus family. Nat Meth. 2005;2:269-76.
51. Omoto S, Fujii Y. Regulation of human immunodeficiency virus 1 transcription by nef microRNA. J Gen Virol. 2005;86:751-5.
52. Omoto S, Ito M, Tsutsumi Y, et al. HIV-1 nef suppression by virally encoded microRNA. Retrovirology. 2004;1:44.
53. Weinberg M, Morris K. Are viral-rncoded microRNAs mediating latent HIV-1 infection? DNA Cell Biol. 2006;25:223-31.
54. Bennasser Y, Le S, Benkirane M, Jeang K. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity. 2005;22:607-19.
55. Bennasser Y, Le S, Yeung M, Jeang K. HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology. 2004;1:43.
56. Couturier J, Root-Bernstein R. HIV may produce inhibitory microRNAs (miRNAs) that block production of CD28, CD4 and some interleukins. J Theor Biol. 2005;235:169-84.
57. Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLos Pathogens. 2006;2:236-47.
58. Cai X, Lu S, Zhang Z, Gonzalez C, Damania B, Cullen B. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci USA. 2005;102: 5570-5.
59. Cai X, Li G, Laimins L, Cullen B. Human papillomavirus genotype 31 does not express detectable microRNA levels during latent or productive virus replication. J Virol. 2006;80:10890-3.
60. Lin J, Cullen B. Analysis of the interaction of primate retroviruses with the human RNA interference machinery. J Virol. 2007;81:12218-26.
61. Bennasser Y, Jeang K. HIV-1 Tat interaction with Dicer: requirement for RNA. Retrovirology. 2006;3:95.
62. Coley W, VanDuyne R, Carpio L, et al. Absence of DICER in monocytes and its regulation by HIV-1. J Biol Chem. 2010;285:31930-43.
63. Ouellet D, Plante I, Landry P, et al. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res. 2008;36:2353-65.
64. Gatignol A, Buckler-White A, Berkhout B, Jeang K. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science. 1991;251:1597-600.
65. Klase Z, Kale P, Winograd R, et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol. 2007;8:63.
66. Klase Z, Winograd R, Davis J, et al. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology. 2009;6:18.
67. Kestler H, Ringler D, Mori K, et al. Importance of the nef Gene for maintenance of high virus loads and for development of AIDS. Cell. 1991;65:651-62.
68. Yamamoto T, Omoto S, Mizuguchi M, et al. Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replication. Microbiol Immunol. 2002;46:809-17.
69. Kaul D, Ahlawat A, Gupta S. HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection. Mol Cell Biochem. 2009;323:143-8.
70. Lamers S, Fogel G, McGrath M. HIV-miR-H1 evolvability during HIV pathogenesis. Biosystems. 2010;101:88-96.
71. Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-8.
72. Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol. 2002; 169:5196-201.
73. Chang L, Liu X, He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Therapy. 2005;12:1133-44.
74. Coburn G, Cullen B. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol. 2002;76:9225-31.
75. Jacque J, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 2002;418:435-8.
76. Bowden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 2004;32:1154-8.
77. Anderson J, Li M, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther. 2007; 15:1182-8.
78. Kumar P, Ban H, Kim S, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134:577-86.
79. Kirchhoff F. Silencing HIV-1 in vivo. Cell. 2008;134:566-8.
80. Santaris Pharma A/S Advances miravirsen, the first microRNA targeted drug to enter chinical trials, into phase 2 to treat patients infected with hepatitis C virus. Clinical Trials Week. 2010;309.
81. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3:1.
82. Lanford R, Hildebrandt-Eriksen E, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198-20
83. Janssen H, Reesink H, Zeuzem S, et al. A randomized, double-blind, placebo (plb) controlled safety and anti-viral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment naïve patients with genotype 1 (gt1) chronic HCV infection [abstract]. Hepatology. 2011;54:1430.
84. Beal J, Hakim A. Therapy Analysis - microRNA. Pharmaprojects Update Analysis. 2008;29(4).
85. Wahid F, Shehzad A, Khan T, Kim Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010; 1803:1231-43.
86. Kulkarni S, Savan R, Qi Y, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature. 2011; 472:495-8.
87. Kerrigan D. Control of HIV through a cell surface protein, HLA-C, and its complicated regulation. In the Journals, Centre for Cancer Research. 2011.
88. Das A, Brummelkamp T, Westerhout E, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004;78:2601-5.
89. Roberts A, Lewis A, Jopling C. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci. 2011;102:101-39.
90. Sung T, Rice A. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog. 2009;5:e1000263.